Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)

Public release date: 7-Sep-2011
[ | E-mail | Share ]

Contact: Emma Dickinson
edickinson@bmjgroup.com
44-020-738-36529
BMJ-British Medical Journal

Biological agents for rheumatoid arthritis associated with increased skin cancer risk

Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta analysis

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

She favors animal prints, and I found one of a woman reclining in a hammock. If she could kick the ball they way she liked to kick me in the knee, I'd see to it she played for my team every time.. I'll find someone to give it to. Maybe it's because I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much.I have loved folk art paintings that depict the world of black Americans. I saw a painting he did of a fishing scene but I chose not to buy it. It's called First Trolley to Van Nuys and shows the center of a town filled with people. Now we're very close.Another painting that I admire is called Howard in 1944.One of my favorite paintings was done in 1962 by Bill Dodge. Still,.....

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors over the long term were at increased risk of cancer either. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk. TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add. . The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall. "This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add. . The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. The pooled risk from There is a subcategory of folk art paintings that depict the world of black Americans. One of my favorites that she had was done by John Roeder. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. I saw a painting he did of a fishing scene but I chose not to buy it.Another painting that I admire is called Howard in 1944.There is a water scene that I really like painted in 1940.My sister also shares my love for folk art. It's too bad my parents didn't let her play football with us.One of the most famous American artists is Thomas Chambers. I'll find someone to give it to. Maybe it's because I spent a lot of time with my grandmother and her house was full of them. Still, they are a joy to behold. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. It's a beautiful painting but it's just too depressing to hang anywhere. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana. It's called First Trolley to Van Nuys and shows the center of a town filled with people. She looked so relaxed, that I could imagine what it felt like to lie there myself. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. Now we're very close. It was painted in 1988 by Reverend

rthritis treat athritis treat arhritis treat artritis treat arthitis treat arthrtis treat arthriis treat arthrits treat arthriti treat arthritis reat arthritis teat arthritis trat arthritis tret arthritis trea srthritis treat aethritis treat atthritis treat arrhritis treat aryhritis treat artgritis treat artjritis treat artheitis treat arthtitis treat arthrutis treat arthrotis treat arthriris treat arthriyis treat arthritus treat arthritos treat arthritia treat arthritid treat arthritis rreat arthritis yreat arthritis teeat arthritis tteat arthritis trwat arthritis trrat arthritis trest arthritis trear arthritis treay rathritis treat atrhritis treat arhtritis treat artrhitis treat arthirtis treat arthrtiis treat arthriits treat arthritsi treat arthriti streat arthritis rteat arthritis terat arthritis traet arthritis treta arthritis trea aarthritis treat arrthritis treat artthritis treat arthhritis treat arthrritis treat arthriitis treat arthrittis treat arthritiis treat arthritiss treat arthritis ttreat arthritis trreat arthritis treeat arthritis treaat arthritis treatt

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)

Public release date: 7-Sep-2011
[ | E-mail | Share ]

Contact: Emma Dickinson
edickinson@bmjgroup.com
44-020-738-36529
BMJ-British Medical Journal

Biological agents for rheumatoid arthritis associated with increased skin cancer risk

Malignancies associated with tumor necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta analysis

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.